Spero Inc.
↗Seoul, South Korea
Spero Inc. is a specialized Decentralized Clinical Trial (DCT) Contract Research Organization (CRO) based in South Korea. Established as a subsidiary of CRScube Inc., a leading eClinical solution provider, Spero focuses on providing integrated digital solutions to accelerate and modernize clinical research. Their service suite includes decentralized clinical development, medical writing, project management, and data management.
The company is known for its proprietary technology platform, iSPERO, which integrates various eClinical tools such as eConsent (cubeCONSENT 3.0), ePRO, and Centralized Monitoring (VIA/cubeRBQM). Spero aims to reduce the burden on both patients and sites by enabling remote participation and real-time data monitoring, aligning with the latest ICH E6(R3) regulatory guidelines.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$10M-$50M (estimated parent revenue context)
Founded:2021
Ownership:subsidiary
Status:operating
FUNDING
Stage:Subsidiary
Investors:CRScube Inc.
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Digital Therapeutics, Small Molecule, Biologics
Active Trials:140
Trial Phases:Phase 1: 30 | Phase 2: 50 | Phase 3: 40 | Phase 4: 20
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:CRScube Inc.
Subsidiaries:Ispero LLC (US Branch)
Key Partnerships:Seoul Bumin Hospital (Clinical Trial Center), KoNECT (Korea National Enterprise for Clinical Trials), MFDS (Ministry of Food and Drug Safety, Korea)
COMPETITION
Position:Emerging
Competitors:Medable, Science 37, DreamCIS, LSK Global PS, Veeva Systems
LEADERSHIP
Key Executives:
Ki-don Kim - CEO of Parent (CRScube)
LINKS
Website:ispero.io
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Spero Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.